Literature DB >> 27013367

Palliative Management of Unresectable Pancreas Cancer.

Katherine E Poruk1, Christopher L Wolfgang2.   

Abstract

Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States. Surgical resection offers the best opportunity for prolonged survival but is limited to patients with locally resectable disease without distant metastases. Regrettably, most patients are diagnosed at a point in which curative surgery is no longer a treatment option. In these patients, management of symptoms becomes paramount to improve quality of life and potentially increase survival. This article reviews the palliative management of unresectable pancreatic cancer, including potential palliative resection, surgical and endoscopic biliary and gastric decompression, and pain control with celiac plexus block.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biliary decompression; Celiac plexus block; Gastric outlet obstruction; Metastatic; Palliative bypass; Pancreatic adenocarcinoma; Unresectable

Mesh:

Year:  2016        PMID: 27013367     DOI: 10.1016/j.soc.2015.11.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

1.  Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study.

Authors:  Audrey S Kulaylat; Katelin A Mirkin; Christopher S Hollenbeak; Joyce Wong
Journal:  J Gastrointest Oncol       Date:  2017-08

2.  Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.

Authors:  Morgan Michalet; Karl Bordeau; Marie Cantaloube; Simon Valdenaire; Pierre Debuire; Sebastien Simeon; Fabienne Portales; Roxana Draghici; Marc Ychou; Eric Assenat; Marie Dupuy; Sophie Gourgou; Pierre-Emmanuel Colombo; Sebastien Carrere; François-Regis Souche; Norbert Aillères; Pascal Fenoglietto; David Azria; Olivier Riou
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

3.  Upregulated GDF-15 expression facilitates pancreatic ductal adenocarcinoma progression through orphan receptor GFRAL.

Authors:  Zhiping Zhao; Junfeng Zhang; Liangyu Yin; Jiali Yang; Yao Zheng; Mengjie Zhang; Bing Ni; Huaizhi Wang
Journal:  Aging (Albany NY)       Date:  2020-11-17       Impact factor: 5.682

4.  Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.

Authors:  William T Arscott; Kevin T Nead; Adham Bear; Sriram Venigalla; Jacob Shabason; John N Lukens; John P Plastaras; Andrzej Wojcieszynski; James Metz; Mark O'Hara; Kim A Reiss; Ursina Teitelbaum; Arturo Loaiza-Bonilla; Jeffrey Drebin; Major K Lee; Stuti G Shroff; Edgar Ben-Josef
Journal:  Am J Clin Oncol       Date:  2021-09-01       Impact factor: 2.339

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.